Cross-immune tolerance: Conception and its potential significance on transplantation tolerance

Cellular and Molecular Immunology

Volumn 7, Issue 1, 2010, Pages 20-25

  Zhao, Yong ^a   Li, Xianchang ^b  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Crossreactivity; T cell repertoire; Tolerance; Transplantation

Indexed keywords

ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ALLOIMMUNITY; CONCEPTION; CROSS REACTION; IMMUNOLOGICAL TOLERANCE; REVIEW; RISK; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE; ANIMAL; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; CELL HETEROGENEITY; CELL SPECIFICITY; CELLULAR IMMUNITY; GRAFT REJECTION; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; MAJOR HISTOCOMPATIBILITY COMPLEX; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS INFECTION; XENOTRANSPLANTATION;

ANIMALS; CROSS REACTIONS; GRAFT SURVIVAL; HUMANS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE;

EID: 75949107016     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.101     Document Type: Review

References (59)

1. Ashwell JD, Chen C, Schwartz RH. High frequency and nonrandom distribution of alloreactivity in T cell clones selected for recognition of foreign antigen in association with self class II molecules. J Immunol 1986; 136: 389-395.
2. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973-981.
3. Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895.
4. Finberg R, Burakoff SJ, Cantor H, Benacerraf B. Biological significance of alloreactivity: T cells stimulated by Sendai virus-coated syngeneic cells specifically lyse allogeneic target cells. Proc Natl Acad Sci USA 1978; 75: 5145-5149.
5. Pantenburg B, Heinzel F, Das L, Heeger PS, Valujskikh A. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 2002; 169: 3686-3693.
6. Taylor DK, Neujahr D, Turka LA. Heterologous immunity and homeostatic proliferation as barriers to tolerance. Curr Opin Immunol 2004; 16: 558-564.
7. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly crossreactive pathogens. Nat Immunol 2002; 3: 627-634.
8. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19: 395-404.
9. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003; 196: 147-160.
10. Sachs DH. Tolerance: of mice and men. J Clin Invest 2003; 111: 1819-1821.
11. Zhao Y, Li XC. Transplant tolerance: is it really free of concerns? Trends Immunol 2007; 28: 376-377.
12. Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R. High level of cross-reactivity in influenza virus hemagglutinin-specific CD41 T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol 2005; 169: 31-38.
13. Hausmann S, Martin M, Gauthier L, Wucherpfennig KW. Structural features of autoreactive TCR that determine the degree of degeneracy in peptide recognition. J Immunol 1999; 162: 338-344.
14. Zhao Y, Gran B, Pinilla C, Markovic-Plese S, Hemmer B, Tzou A et al. Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J Immunol 2001; 167: 2130-2141.
15. Bhardwaj V, Kumar V, Geysen HM, Sercarz EE. Degenerate recognition of a dissimilar antigenic peptide by myelin basic protein-reactive T cells. Implications for thymic education and autoimmunity. J Immunol 1993; 151: 5000-5010.
16. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991; 65: 319-331.
17. Casrouge A, Beaudoing E, Dalle S, Pannetier C, Kanellopoulos J, Kourilsky P. Size estimate of the alpha beta TCR repertoire of naive mouse splenocytes. J Immunol 2000; 164: 5782-5787.
18. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA 1998; 95: 14447-14452.
19. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human alphabeta T cell receptor diversity. Science 1999; 286: 958-961.
20. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4: 123-132.
21. Reiser JB, Darnault C, Gregoire C, Mosser T, Mazza G, Kearney A et al. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat Immunol 2003; 4: 241-247.
22. Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999; 402: 255-262.
23. Kersh GJ, Allen PM. Essential flexibility in the T-cell recognition of antigen. Nature 1996; 380: 495-498.
24. Reay PA, Kantor RM, Davis MM. Use of global amino acid replacements to define the requirements for MHCbinding and T cell recognition of moth cytochrome c (93-103). J Immunol 1994; 152: 3946-3957.
25. Gautam AM, Lock CB, Smilek DE, Pearson CI, Steinman L, McDevitt HO. Minimum structural requirements for peptide presentation by major histocompatibility complex class II molecules: implications in induction of autoimmunity.Proc Natl Acad Sci USA 1994; 91: 767-771.
26. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 940-943.
27. Ignatowicz L, Kappler J, Marrack P. The repertoire of T cells shaped by a single MHC/ peptide ligand. Cell 1996; 84: 521-529.
28. Ignatowicz L, Rees W, Pacholczyk R, Ignatowicz H, Kushnir E, Kappler J et al. T cells can be activated by peptides that are unrelated in sequence to their selecting peptide. Immunity 1997; 7: 179-186.
29. Wucherpfennig KW. T cell receptor crossreactivity as a general property of T cell recognition. Mol Immunol 2004; 40: 1009-1017.
30. Cohn M. Degeneracy, mimicry and crossreactivity in immune recognition. Mol Immunol 2005; 42: 651-655.
31. Page KR, Scott AL, Manabe YC. The expanding realm of heterologous immunity: friend or foe? Cell Microbiol 2006; 8: 185-196.
32. Fujinami RS, Oldstone MB. Molecular mimicry as a mechanism for virus-induced autoimmunity. Immunol Res 1989; 8: 3-15.
33. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
34. Warnock MG, Goodacre JA. Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases. Br J Rheumatol 1997; 36: 1144-1150.
35. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9: 921-927.
36. Daniel C, Horvath S, Allen PM. A basis for alloreactivity:MHChelical residues broaden peptide recognition by the TCR. Immunity 1998; 8: 543-552.
37. Blattman JN, Antia R, Sourdive DJ, Wang X, Kaech SM, Murali-Krishna K et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 2002; 195: 657-664.
38. Hornick PI, Brookes PA, Mason PD, Taylor KM, Yacoub MH, Rose ML et al. Optimizing a limiting dilution culture system for quantifying the frequency of interleukin-2-producing alloreactive T helper lymphocytes. Transplantation 1997; 64: 472-479.
39. Welsh RM, Markees TG, Woda BA, Daniels KA, Brehm MA, Mordes JP et al. Virusinduced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 2000; 74: 2210-2218.
40. Williams MA, Onami TM, Adams AB, Durham MM, Pearson TC, Ahmed R et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002; 169: 5387-5391.
41. Burrows SR, Silins SL, Khanna R, Burrows JM, Rischmueller M, McCluskey J et al. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol 1997; 27: 1726-1736.
42. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994; 179: 1155-1161.
43. Yang H, Welsh RM. Induction of alloreactive cytotoxic T cells by acute virus infection of mice. J Immunol 1986; 136: 1186-1193.
44. Carlquist JF, Shelby J, Shao YL, Greenwood JH, Hammond ME, Anderson JL. Accelerated rejection of murine cardiac allografts by murine cytomegalovirusinfected recipients. Lack of haplotype specificity. J Clin Invest 1993; 91: 2602-2608.
45. Landais E, Morice A, Long HM, Haigh TA, Charreau B, BonnevilleMet al. EBV-specific CD41 T cell clones exhibit vigorous allogeneic responses. J Immunol 2006; 177: 1427-1433.
46. Williams MA, Tan JT, Adams AB, Durham MM, Shirasugi N, Whitmire JK et al. Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance. J Immunol 2001; 167: 4987-4995.
47. Vu MD, Clarkson MR, Yagita H, Turka LA, Sayegh MH, Li XC. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol 2006; 176: 1394-1401.
48. Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak JA et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267-2275.
49. Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, Waldmann H et al. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 2006; 176: 4632-4639.
50. Zhao Y, Sykes M. Resistance to monoclonal antibody-induced CD81 T-cell depletion in thymectomized MHC class II-deficient mice. Transplantation 1997; 64: 489-494.
51. Kean LS, Gangappa S, Pearson TC, Larsen CP. Transplant tolerance in non-human primates: progress, current challenges and unmet needs. Am J Transplant 2006; 6: 884-893.
52. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417-424.
53. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
54. Blankenstein T, Schuler T. Cross-priming versus cross-tolerance: are two signals enough? Trends Immunol 2002; 23: 171-173.
55. Heath WR, Kurts C, Miller JF, Carbone FR. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998; 187: 1549-1553.
56. Waldmann H, Adams E, Fairchild P, Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev 2006; 212: 301-313.
57. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M et al. Immunologic tolerance maintained by CD251 CD41 regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
58. Karim M, Feng G, Wood KJ, Bushell AR. CD251CD41 regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005; 105: 4871-4877.
59. Ballet C, Roussey-Kesler G, Aubin JT, Brouard S, Giral M, Miqueu P et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 2006; 6: 2796-2801.